Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Moleculin Biotech ( (MBRX) ) has provided an announcement.
On June 18, 2025, Moleculin Biotech announced that the FDA has approved a single pediatric study to evaluate Annamycin in combination with Cytarabine as a second-line therapy for pediatric patients with relapsed/refractory acute myeloid leukemia. The study will include patients as young as six months, and Moleculin plans to initiate the pediatric clinical study in the second half of 2027. This development is significant for Moleculin as it aligns with their ongoing efforts to advance Annamycin, which has shown no cardiotoxicity in adult trials, positioning the company favorably in the pediatric oncology market.
The most recent analyst rating on (MBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates targeting hard-to-treat tumors and viruses. The company’s lead program, Annamycin, is designed to be a non-cardiotoxic anthracycline for treating relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.
Average Trading Volume: 600,285
Technical Sentiment Signal: Sell
Current Market Cap: $9.68M
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.